Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: outcome and prognostic factors. The Chronic Myeloid Leukemia Subcommittee of the GETH (Grupo Español de Trasplante Hemopoyético)

Bone Marrow Transplantation volume 36, pages 301–306 (2005)Cite this article

Summary:

In order to analyze the outcome of patients with chronic myeloid leukemia (CML) who relapse after allogeneic stem cell transplantation (SCT), we investigated data from 107 patients reported to the Spanish Registry, GETH. In all, 93 (87%) patients were treated after relapse; 36 out of 49 that failed to achieve a response received a second relapse-treatment, and seven a third one. At the last follow-up, the number of patients in molecular or cytogenetic remission was 29 and 13, respectively. Overall survival and progression-free survival after relapse were 53.6% (95% CI: 42.9–64.2) and 52% (95% CI: 41–63) at 5 years, respectively. In multivariate analysis, survival was significantly related to CML phase at relapse (cytogenetic or chronic phase vs advanced phases) and time from transplant to relapse (<1 vs ⩾1 year). Patients with no adverse factors had a better survival compared with patients with one or two adverse features (65 vs 35 vs 0%, respectively). We conclude that a significant proportion of CML patients that relapse after transplantation can regain complete and long-lasting remissions with one or more salvage therapies. Disease stage at relapse and time from transplant to relapse should be taken into account when comparing results of different salvage treatments.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Goldman JM, Apperley JF, Jones L et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 1986; 14: 202–207.

    Article  Google Scholar 

  2. Thomas ED, Clift RA, Fefer A et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104: 155–163.

    Article  CAS  PubMed  Google Scholar 

  3. van Rhee F, Szydlo RM, Hermans J et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20: 553–560.

    Article  CAS  PubMed  Google Scholar 

  4. Devergie A, Reiffers J, Vernant JP et al. Long-term follow-up after bone marrow transplantation for chronic myelogenous leukemia: factors associated with relapse. Bone Marrow Transplant 1990; 5: 379.

    CAS  PubMed  Google Scholar 

  5. Martin PJ, Clift RA, Fisher LD et al. HLA-identical marrow transplantation during accelerate phase chronic myelogenous leukemia: analysis of survival and remission duration. Blood 1988; 72: 1978.

    CAS  PubMed  Google Scholar 

  6. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for the treatment of chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806–814.

    Article  CAS  PubMed  Google Scholar 

  7. Higano CS, Chielens D, Raskind W et al. Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation. Blood 1997; 82: 3211–3219.

    Google Scholar 

  8. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462–2465.

    CAS  PubMed  Google Scholar 

  9. Cullis JO, Jiang YZ, Scwarer AP et al. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 1992; 79: 1379–1381.

    CAS  PubMed  Google Scholar 

  10. Dazzi F, Szydlo RM, Cross N et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96: 2712–2716.

    CAS  PubMed  Google Scholar 

  11. Guglielmi C, Arcese W, Dazzi F et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002; 100: 397–405.

    Article  CAS  PubMed  Google Scholar 

  12. Arcese W, Goldman JM, D’Arcangelo E et al. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Myeloid Leukemia Working Party. European Bone Marrow Transplantation Group. Blood 1993; 82: 3211–3219.

    CAS  PubMed  Google Scholar 

  13. Olavarria E, Ottmann OG, Deininger M et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2003; 17: 1707–1712.

    Article  CAS  PubMed  Google Scholar 

  14. Kantarjian HM, O’Brien S, Cortes JE et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002; 100: 1590–1595.

    CAS  PubMed  Google Scholar 

  15. Guglielmi C, Arcese W, Hermans J et al. Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. Blood 2000; 95: 3328–3334.

    CAS  PubMed  Google Scholar 

  16. Gratwohl A, Hermans J, Goldman JM et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet 1998; 352: 1087–1092.

    Article  CAS  PubMed  Google Scholar 

  17. Hughes TP, Morgan GJ, Martiat P, Goldman JM . Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood 1991; 77: 874–878.

    CAS  PubMed  Google Scholar 

  18. Hochhaus A, Weisser A, La Rosee P et al. Detection and quantification of residual disease in chronic myelogenous leukemia. Leukemia 2000; 14: 998–1005.

    Article  CAS  PubMed  Google Scholar 

  19. Olavarria E, Kanfer E, Szydlo R et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001; 97: 1560–1565.

    Article  CAS  PubMed  Google Scholar 

  20. Arcese W, Mauro FR, Alimema G et al. Interferon therapy for Ph1-positive CML patients relapsing after T-cell depleted allogeneic bone marrow transplantation. Bone Marrow Transplant 1990; 5: 309–315.

    CAS  PubMed  Google Scholar 

  21. Steegman JL, Casado LF, Tomas JF et al. Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23: 483–488.

    Article  Google Scholar 

  22. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037.

    Article  CAS  PubMed  Google Scholar 

  23. Kantarjian H, Sawyers C, Hochhaus A, et al, The International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–652.

    Article  CAS  PubMed  Google Scholar 

  24. Cervantes F on behalf of the IRIS Study Group. Durability of responses to imatinib in newly diagnosed chronic-phase chronic myeloid leukemia (CML): 24-month-update from the IRIS study. Blood 2003; 102 (Suppl. 1): 181a.

  25. Mattei D, Saglio G, Gottardi E et al. Persisting molecular remission ten years after donor lymphocyte infusion for hematologic relapse in chronic myeloid leukemia. Haematologica 2001; 86: 545–546.

    CAS  PubMed  Google Scholar 

  26. Raiola AM, Van Lint MT, Valbonesi M et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant 2003; 31: 687–693.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology Department, Bone Marrow Transplantation Section, Hospital Clínic, Barcelona, Spain

    C Martínez, V Gomez, J F Tomás, R Parody, A Sureda, G Sanz, C Cañizo, J L Díez & C Boqué

Authors
  1. C Martínez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V Gomez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J F Tomás
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Parody
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Sureda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Sanz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Cañizo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J L Díez
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C Boqué
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the CML Subcommittee of the Spanish Group of Hematopoietic Transplantation (Grupo Español de Trasplante Hemopoyético, GETH)

Corresponding author

Correspondence to C Martínez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martínez, C., Gomez, V., Tomás, J. et al. Relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: outcome and prognostic factors. The Chronic Myeloid Leukemia Subcommittee of the GETH (Grupo Español de Trasplante Hemopoyético). Bone Marrow Transplant 36, 301–306 (2005). https://doi.org/10.1038/sj.bmt.1705063

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705063

Keywords

Search

Advanced search

Quick links